Potential public health and economic impact of maternal vaccination with bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccine for the prevention of acute respiratory infection among infants in the United States
Background The U.S. Advisory Committee on Immunization Practices recommends use of bivalent stabilized prefusion F subunit vaccine (RSVpreF) among pregnant persons to protect their infants against lower respiratory tract illness due to RSV (RSV-LRTI).Research design and methods Using a cohort model...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Expert Review of Vaccines |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/14760584.2025.2503966 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849714989847281664 |
|---|---|
| author | Ahuva Averin Amy W. Law Derek Weycker Mark Atwood Erin Quinn Jessica E. Atwell Alejandro Cane Bradford D. Gessner Sarah Pugh Kimberly M. Shea |
| author_facet | Ahuva Averin Amy W. Law Derek Weycker Mark Atwood Erin Quinn Jessica E. Atwell Alejandro Cane Bradford D. Gessner Sarah Pugh Kimberly M. Shea |
| author_sort | Ahuva Averin |
| collection | DOAJ |
| description | Background The U.S. Advisory Committee on Immunization Practices recommends use of bivalent stabilized prefusion F subunit vaccine (RSVpreF) among pregnant persons to protect their infants against lower respiratory tract illness due to RSV (RSV-LRTI).Research design and methods Using a cohort model depicting clinical outcomes and economic costs of RSV acute respiratory infection (RSV-ARI) among US infants from birth to age 1 year, we evaluated the impact of seasonally administered maternal RSVpreF versus no intervention. Outcomes included cases of medically attended RSV-ARI, RSV-related deaths, medical costs, and indirect costs. Costs were reported in 2023 US$.Results Among the 3.7 million US infants aged <12 months each year, a total of 1,148,967 RSV-ARI cases (hospital: 48,384; emergency department [ED]: 246,118; outpatient clinic [OC]: 854,465) were projected to occur, yielding total annual costs of $2.4 billion (direct: $1.7B; indirect: $0.7B). With 54.9% uptake, RSVpreF would prevent 89,908 cases (hospital: 10,308; ED: 20,538; OC: 59,062), corresponding with a $368 million decrease (direct: $286 M; indirect: $81 M) in total 1-year costs.Conclusion Even with limited uptake and without considering benefits to pregnant persons or reductions in RSV-related sequelae, maternal vaccination with RSVpreF would substantially reduce the public health and economic burden of RSV-ARI in US infants. |
| format | Article |
| id | doaj-art-5743310b46e44d358e6dc34eb7379538 |
| institution | DOAJ |
| issn | 1476-0584 1744-8395 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Expert Review of Vaccines |
| spelling | doaj-art-5743310b46e44d358e6dc34eb73795382025-08-20T03:13:32ZengTaylor & Francis GroupExpert Review of Vaccines1476-05841744-83952025-12-0124140341110.1080/14760584.2025.2503966Potential public health and economic impact of maternal vaccination with bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccine for the prevention of acute respiratory infection among infants in the United StatesAhuva Averin0Amy W. Law1Derek Weycker2Mark Atwood3Erin Quinn4Jessica E. Atwell5Alejandro Cane6Bradford D. Gessner7Sarah Pugh8Kimberly M. Shea9Evidence & Strategy- Advisory, Avalere Health, Washington, DC, USAGlobal Access and Value, Pfizer Inc, New York, NY, USAEvidence & Strategy- Advisory, Avalere Health, Washington, DC, USAEvidence & Strategy- Advisory, Avalere Health, Washington, DC, USAEvidence & Strategy- Advisory, Avalere Health, Washington, DC, USAGlobal Medical and Scientific Affairs, Pfizer Inc, New York, NY, USAUS Medical and Scientific Affairs, Pfizer Inc, Collegeville, PA, USAGlobal Medical and Scientific Affairs, Pfizer Inc, New York, NY, USAUS Medical and Scientific Affairs, Pfizer Inc, Collegeville, PA, USAGlobal Access and Value, Pfizer Inc, New York, NY, USABackground The U.S. Advisory Committee on Immunization Practices recommends use of bivalent stabilized prefusion F subunit vaccine (RSVpreF) among pregnant persons to protect their infants against lower respiratory tract illness due to RSV (RSV-LRTI).Research design and methods Using a cohort model depicting clinical outcomes and economic costs of RSV acute respiratory infection (RSV-ARI) among US infants from birth to age 1 year, we evaluated the impact of seasonally administered maternal RSVpreF versus no intervention. Outcomes included cases of medically attended RSV-ARI, RSV-related deaths, medical costs, and indirect costs. Costs were reported in 2023 US$.Results Among the 3.7 million US infants aged <12 months each year, a total of 1,148,967 RSV-ARI cases (hospital: 48,384; emergency department [ED]: 246,118; outpatient clinic [OC]: 854,465) were projected to occur, yielding total annual costs of $2.4 billion (direct: $1.7B; indirect: $0.7B). With 54.9% uptake, RSVpreF would prevent 89,908 cases (hospital: 10,308; ED: 20,538; OC: 59,062), corresponding with a $368 million decrease (direct: $286 M; indirect: $81 M) in total 1-year costs.Conclusion Even with limited uptake and without considering benefits to pregnant persons or reductions in RSV-related sequelae, maternal vaccination with RSVpreF would substantially reduce the public health and economic burden of RSV-ARI in US infants.https://www.tandfonline.com/doi/10.1080/14760584.2025.2503966Costs and cost analysisinfantsmaternally acquired immunitypublic healthrespiratory syncytial virusrespiratory syncytial virus vaccine |
| spellingShingle | Ahuva Averin Amy W. Law Derek Weycker Mark Atwood Erin Quinn Jessica E. Atwell Alejandro Cane Bradford D. Gessner Sarah Pugh Kimberly M. Shea Potential public health and economic impact of maternal vaccination with bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccine for the prevention of acute respiratory infection among infants in the United States Expert Review of Vaccines Costs and cost analysis infants maternally acquired immunity public health respiratory syncytial virus respiratory syncytial virus vaccine |
| title | Potential public health and economic impact of maternal vaccination with bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccine for the prevention of acute respiratory infection among infants in the United States |
| title_full | Potential public health and economic impact of maternal vaccination with bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccine for the prevention of acute respiratory infection among infants in the United States |
| title_fullStr | Potential public health and economic impact of maternal vaccination with bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccine for the prevention of acute respiratory infection among infants in the United States |
| title_full_unstemmed | Potential public health and economic impact of maternal vaccination with bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccine for the prevention of acute respiratory infection among infants in the United States |
| title_short | Potential public health and economic impact of maternal vaccination with bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccine for the prevention of acute respiratory infection among infants in the United States |
| title_sort | potential public health and economic impact of maternal vaccination with bivalent respiratory syncytial virus prefusion f rsvpref vaccine for the prevention of acute respiratory infection among infants in the united states |
| topic | Costs and cost analysis infants maternally acquired immunity public health respiratory syncytial virus respiratory syncytial virus vaccine |
| url | https://www.tandfonline.com/doi/10.1080/14760584.2025.2503966 |
| work_keys_str_mv | AT ahuvaaverin potentialpublichealthandeconomicimpactofmaternalvaccinationwithbivalentrespiratorysyncytialvirusprefusionfrsvprefvaccineforthepreventionofacuterespiratoryinfectionamonginfantsintheunitedstates AT amywlaw potentialpublichealthandeconomicimpactofmaternalvaccinationwithbivalentrespiratorysyncytialvirusprefusionfrsvprefvaccineforthepreventionofacuterespiratoryinfectionamonginfantsintheunitedstates AT derekweycker potentialpublichealthandeconomicimpactofmaternalvaccinationwithbivalentrespiratorysyncytialvirusprefusionfrsvprefvaccineforthepreventionofacuterespiratoryinfectionamonginfantsintheunitedstates AT markatwood potentialpublichealthandeconomicimpactofmaternalvaccinationwithbivalentrespiratorysyncytialvirusprefusionfrsvprefvaccineforthepreventionofacuterespiratoryinfectionamonginfantsintheunitedstates AT erinquinn potentialpublichealthandeconomicimpactofmaternalvaccinationwithbivalentrespiratorysyncytialvirusprefusionfrsvprefvaccineforthepreventionofacuterespiratoryinfectionamonginfantsintheunitedstates AT jessicaeatwell potentialpublichealthandeconomicimpactofmaternalvaccinationwithbivalentrespiratorysyncytialvirusprefusionfrsvprefvaccineforthepreventionofacuterespiratoryinfectionamonginfantsintheunitedstates AT alejandrocane potentialpublichealthandeconomicimpactofmaternalvaccinationwithbivalentrespiratorysyncytialvirusprefusionfrsvprefvaccineforthepreventionofacuterespiratoryinfectionamonginfantsintheunitedstates AT bradforddgessner potentialpublichealthandeconomicimpactofmaternalvaccinationwithbivalentrespiratorysyncytialvirusprefusionfrsvprefvaccineforthepreventionofacuterespiratoryinfectionamonginfantsintheunitedstates AT sarahpugh potentialpublichealthandeconomicimpactofmaternalvaccinationwithbivalentrespiratorysyncytialvirusprefusionfrsvprefvaccineforthepreventionofacuterespiratoryinfectionamonginfantsintheunitedstates AT kimberlymshea potentialpublichealthandeconomicimpactofmaternalvaccinationwithbivalentrespiratorysyncytialvirusprefusionfrsvprefvaccineforthepreventionofacuterespiratoryinfectionamonginfantsintheunitedstates |